Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RV299
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RV299 is an investigational small molecule antiviral drug developed for the treatment of respiratory syncytial virus (RSV) infection. It acts as an inhibitor of **nuclear proteins**, targeting viral replication processes. The drug has been evaluated in phase 1 and phase 1b clinical trials to assess its safety, pharmacokinetics, tolerability, and antiviral activity in healthy adults using a viral challenge model with RSV-A Memphis 37b. The studies have shown that orally administered RV299 is safe and well tolerated at tested doses[1][3][4][5][7]. Initial development was by ReViral Ltd., with Pfizer also listed as a sponsor/collaborator in later studies[1].
- Other names
- RV-299RV299RV 299
02
Targets
RSV N (Respiratory syncytial virus nucleoprotein)
Beyond the preview
Go deeper on RV299.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RV299.